Retrospective investigation of tacrolimus combined with an anti‐tumor necrosis factorα antibody as remission induction therapy for refractory ulcerative colitis: Efficacy, safety, and relapse rate

BACKGROUND AND AIM: Combined therapy with tacrolimus (TAC) and an anti‐tumor necrosis factorα (TNFα) antibody is used to induce remission in ulcerative colitis (UC) patients who have not responded to monotherapy with either drug. We evaluated the efficacy and safety of combined therapy, as well as t...

Full description

Saved in:
Bibliographic Details
Published in:JGH Open
Main Authors: Ito, Ayumi, Omori, Teppei, Nakamura, Shinichi, Tokushige, Katsutoshi
Format: Artigo
Language:Inglês
Published: Wiley Publishing Asia Pty Ltd 2019
Subjects:
Original Articles
Online Access:https://ncbi.nlm.nih.gov/pmc/articles/PMC6891029/
https://ncbi.nlm.nih.gov/pubmed/31832554
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1002/jgh3.12197
Tags: Add Tag
No Tags, Be the first to tag this record!

Similar Items